Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease
Thibaut Duparc, … , Souad Najib, Laurent O. Martinez
Thibaut Duparc, … , Souad Najib, Laurent O. Martinez
Published March 12, 2024
Citation Information: JCI Insight. 2024;9(8):e175623. https://doi.org/10.1172/jci.insight.175623.
View: Text | PDF
Research Article Hepatology Metabolism

P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease

  • Text
  • PDF
Abstract

Excessive lipolysis in white adipose tissue (WAT) leads to insulin resistance (IR) and ectopic fat accumulation in insulin-sensitive tissues. However, the impact of Gi-coupled receptors in restraining adipocyte lipolysis through inhibition of cAMP production remained poorly elucidated. Given that the Gi-coupled P2Y13 receptor (P2Y13-R) is a purinergic receptor expressed in WAT, we investigated its role in adipocyte lipolysis and its effect on IR and metabolic dysfunction-associated steatotic liver disease (MASLD). In humans, mRNA expression of P2Y13-R in WAT was negatively correlated to adipocyte lipolysis. In mice, adipocytes lacking P2Y13-R displayed higher intracellular cAMP levels, indicating impaired Gi signaling. Consistently, the absence of P2Y13-R was linked to increased lipolysis in adipocytes and WAT explants via hormone-sensitive lipase activation. Metabolic studies indicated that mice lacking P2Y13-R showed a greater susceptibility to diet-induced IR, systemic inflammation, and MASLD compared with their wild-type counterparts. Assays conducted on precision-cut liver slices exposed to WAT conditioned medium and on liver-specific P2Y13-R–knockdown mice suggested that P2Y13-R activity in WAT protects from hepatic steatosis, independently of liver P2Y13-R expression. In conclusion, our findings support the idea that targeting adipose P2Y13-R activity may represent a pharmacological strategy to prevent obesity-associated disorders, including type 2 diabetes and MASLD.

Authors

Thibaut Duparc, Emilia Gore, Guillaume Combes, Diane Beuzelin, Julie Pires Da Silva, Vanessa Bouguetoch, Marie-Adeline Marquès, Ana Velazquez, Nathalie Viguerie, Geneviève Tavernier, Peter Arner, Mikael Rydén, Dominique Langin, Nabil Sioufi, Mohamad Nasser, Cendrine Cabou, Souad Najib, Laurent O. Martinez

×

Figure 10

Increased liver steatosis associated with the lack of P2Y13-R depends on adipose tissue lipolysis.

Options: View larger image (or click on image) Download as PowerPoint
Increased liver steatosis associated with the lack of P2Y13-R depends on...
(A) Experimental design of liver-specific P2Y13-R–KD (P2Y13-R–KDliver) and control mice. (B) Hepatic TG concentration from P2Y13-R–KDliver and control mice fed HFSC diet for 16 weeks (n = 10 mice per group). (C) Study design for precision-cut liver slice (PCLS) experiments. (D and E) TG concentrations in liver slices from chow diet–fed WT and P2Y13-R–KO mice in control condition or after 48 hours’ treatment with conditioned media originating from CL316,243-stimulated iWAT or eWAT explants originating from WT or P2Y13-R–KO mice that were HFSC fed for 40 weeks (n = 4 mice per group). (F) TG concentrations in liver slices from chow diet–fed WT and P2Y13-R–KO mice after 48 hours of treatment with FAFI media containing oleic acid, palmitic acid, insulin, and fructose. Open blue and red circles represent PCLS from WT and P2Y13-R–KO mice, respectively (n = 3 mice per group). All data are expressed as mean ± SEM. **P < 0.01, ***P < 0.001 (B, 2-tailed unpaired Student’s t test was used for genotype comparison; D–F, 2-way ANOVA followed by Bonferroni’s post hoc test was used for group comparison). CM, conditioned media; eWAT, epididymal white adipose tissue; FAFI, fatty acids, fructose and insulin; HFSC, high-fat high-sucrose high-cholesterol; iWAT, inguinal white adipose tissue; KD, knockdown; KO, knockout; ns, nonsignificant; TG, triglyceride; WT, wild-type.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts